Read below for the latest updates regarding EXPAREL and the latest pricing and reimbursement information that may be important for your site(s) of care.
Recent Clinical Data
EXPAREL is the only FDA approved single dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies. New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures.
- Interscalene brachial plexus nerve block for upper extremity
- Adductor canal block for lower extremity procedures
- Sciatic nerve block in the popliteal fossa for lower extremity procedures
- Pediatric Approval for children ages 6-17
340B Pricing
340B pricing available for EXPAREL as of October 2022.
For more information, please contact your representative.
Now on selected GPO contracts
Connect with us for more specific information about GPO Contracts.
We currently have GPO contracts with the following partners:
- Sevāredent
- Premier
-
NOPAIN Act
Reimbursement for EXPAREL in the hospital outpatient department beginning January 1, 2025
- The NOPAIN Act is a federal mandate that requires Medicare to reimburse for non-opioids, like EXPAREL® (bupivacaine liposome injectable suspension), used during all surgeries conducted in the hospital outpatient department (HOPD) setting. This will expand Medicare reimbursement beyond the ambulatory surgery center (ASC) which is currently available for EXPAREL using code C9290.
- Read more about the NOPAIN Act
Reimbursement in the ASC for Medicare Patients
EXPAREL is reimbursed for procedures performed in ASCs using the code C9290
- As of January 1, 2024, EXPAREL is reimbursed at $1.41/mg*
- Allowed amount for reimbursement:
$375.06†
266mg (20mL) dose
$187.53†
133mg (10mL) dose
For more information, contact our dedicated reimbursement specialists at
reimbursement@pacira.com or call our Reimbursement Helpline at 1-855-793-9727
14+ Million patients